Clindets Articles
EDQM suspends cert for Chinese APIs
29 April 2009
Perrigo and Cobrek file for generic Evoclin
23 March 2009
Sinclair and York enter UK co-promotion deal
12 January 2009
Valeant buys Dow Pharma for $285M
15 December 2008
Arcutis gets FDA appro for Acanya acne gel
1 December 2008
Strong in vivo data for Targanta's oritavancin
3 November 2008
York buys UK's Derms Dev for L17.5 million
15 October 2007
KV and Beijing Med-Pharm in Chinese Clindesse deal
23 July 2007
KV's fiscal 4th-qtr 2007 sales up 39%
11 June 2007
KV's 4th-qtr 2006 net income increases 16%
19 February 2007
China's SFDA revokes 15 GMP certificates
30 October 2006
Stiefel debuts Duac in Italy
2 October 2006
China approves new drug regulations
14 August 2006
Connetics buys PediaMed sales org
16 January 2006
KV and Richter Gedeon expand license deal
12 December 2005
KV Pharma's fiscal 2005 sees 7% sales rise
20 June 2005
Ventiv in new partnership with Connetics
25 April 2005
KV reports record revenues for 2004
7 February 2005
KV Pharma licenses two women's products for Mexico
17 January 2005
Connetics' Evoclin available in the USA
20 December 2004
KV Pharma's Clindesse cleared in the USA
13 December 2004
Connetics' Evoclin cleared in USA
1 November 2004
Dermik's BenzaClin acne gel available in Canada
31 May 2004
Connetics' Actiza NDA accepted by FDA
15 March 2004
Connetics files NDA for Actiza with FDA
5 January 2004
Connetics sees 4th-qtr product revenues rise 50%
3 February 2003
Strakan launches home-grown acne drug Zindaclin in UK
25 March 2002
Fougera first to market generic clindamycin lotion
11 February 2002
Pharmacia & Paladin sign Canadian distribution deal
28 January 2002
Scotland's Strakan raises L15 million
14 January 2002
Access gets UK approval for Zindaclin
24 October 2001
Watson signs pact with Pharmacia Corp for Cleocin T
15 June 2000
P&U receives FDA OK for Cleocin
17 August 1999
Access Pharmaceuticals To Start Phase II Trials of Topical Acne Drug
12 November 1998
Phase III Data With Hyal/Shire's HyClinda
18 June 1998
HMR JV In S Africa
23 December 1996
Two More Launches For Upjohn's Freedox
24 April 1995
Clindamycin For Necrotizing Fasciitis
24 April 1995
End Of Year Encouraging For US Companies
6 February 1995
Trospectomycin Trials Close To Completion But Future Uncertain
17 October 1994
UPJOHN OUTLINES STRATEGIC DIRECTIONS
18 April 1994
COST-CUTTING IN SPANISH HEALTH CARE
7 March 1994
MERCK AG AN OVERVIEW OF 1992 PERFORMANCE
19 July 1993
UPJOHN PACT WITH GENEVA EXTENDED
5 April 1993
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
FREEZES AT UPJOHN IN STRATEGY REVIEW
8 June 1992
AUGMENTIN AS EFFECTIVE AS COMBO REGIMENS
4 May 1992
UPJOHN'S GLYNASE APPROVED IN USA
27 April 1992
UPJOHN UPDATES ON R&D PROGRESS
13 April 1992
ICI, UPJOHN TO DROP SUMITOMO JVs
20 January 1992
Showing 1-53 of 53 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
